Could one CRISPR dose really replace daily meds for hereditary angioedema?

Early clinical-trial results suggest an in-body CRISPR treatment may sharply reduce attacks by making a one-time edit in liver cells, addressing part of the biological pathway behind hereditary angioedema. That is promising, but trial success is not the same as FDA approval, lifelong durability, or proof for every patient. The key questions now are how long the effect lasts, what off-target or immune risks appear with broader follow-up, and how the treatment compares with effective preventive medicines already available.